Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 11/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725448 | 1.00 | PTGES (0.47) | PTGESALDH1A1POLBCNR2LRRK2 | |
| SCHEMBL10170049 | 0.90 | PTGES (0.48) | PTGESALDH1A1POLBCNR2HTR4 | |
| SCHEMBL11970148 | 0.90 | PTGES (0.48) | PTGESALDH1A1POLBCNR2HTR4 | |
| SCHEMBL11951461 | 0.89 | TAS1R3 (0.42) | PTGESALDH1A1POLBCNR2DRD2 | |
| SCHEMBL1726188 | 0.85 | PTGES (0.44) | PTGESALDH1A1POLBCNR2LRRK2 | |
| SCHEMBL1726190 | 0.85 | PTGES (0.44) | PTGESALDH1A1POLBCNR2LRRK2 | |
| SCHEMBL1671955 | 0.82 | ALDH1A1 (0.51) | PTGESALDH1A1POLBCNR2SCN9A | |
| SCHEMBL1671952 | 0.82 | ALDH1A1 (0.51) | PTGESALDH1A1POLBCNR2SCN9A | |
| SCHEMBL672703 | 0.81 | PTGES (0.44) | PTGESCNR2LRRK2 | |
| SCHEMBL671327 | 0.81 | PTGES (0.44) | PTGESCNR2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| EP-2403852-B1 | 2-AMINOBENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| EP-2403852-B1 | 2-AMINOBENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| EP-2606036-B1 | 2-ANILINOBENZIMIDAZOLE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-8759537-B2 | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20120214786-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120196897-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| EP-2403852-A1 | 3H-IMIDAZO [4, 5 -C]PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| WO-2010100249-A1 | 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196897-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885ALDH1A1 1761/4885POLB 2998/4885 |
| US-20120214786-A1 | NEW COMPOUNDS | PTGER1, PTGS1, PTGES | PTGES 3/4885ALDH1A1 184/4885POLB 2210/4885 |
| US-20130303571-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885ALDH1A1 1761/4885POLB 2998/4885 |
| US-20100256188-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885ALDH1A1 1761/4885POLB 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.